gilead's drug is better in just about every way imaginable. you can get it injected, orally, just 12 weeks, based on trial results, patients would have a much higher chance of actually being cured. some cases as high as 100%. if the fda approves this drug, it will be $5 billion in sales by 2016. $5 billion. makes $11 billion it paid to acquire this, look like a pittance, when there is a lot of chatting that gilead lost its mind. gilead has strong management teams and they don't need a strong global economy. secular growth stories will continue to make money, and the world economy smashes into a retaining wall. you don't stop taking life- saving medicine because of a recession. bottom line, the next 2 1/2 months, gilead and alex i don't know -- alexion are going higher, and every manager wants to show they own what's hot and what's not is not in their portfolio. you can pick these stocks up, and frankly between now and year ends on any weakness. and i speak to elizabeth in florida. elizabeth. >> caller: hey, cramer, solid growth offset concerns

gilead lost its mind.ant, these companies don't need a strong global economy in order to keep growing. they're secular growth stories and will continue to make money even if the world economy smashes into a retaining wall wrush don't stop saying life-saving medicine because of a recession. here's the bottom line. at least for the next two and a half months gilead and alexion are going higher because they've been going higher because they're already hot stocks, and every growth-oriented portfolio manager out there wants to show their clients that they own what's hot and not -- and what's not isn't in their portfolio. that means these stocks are anointed for the fourth quarter. you can pick them up between now and year end on any weakness. next speak to elizabeth in florida. >> caller: hey, cramer. i want to know lexiotica is controlling market share and off set concerns over the euro, so does this italian monopoly seeing you a 20-20 buy or a glaring pass? >> i was over at the haley's, and we were watching "

and let's say vertex and cystic fibrosis might be worth half of gilead, $26 billion, you could stillatch doubles from here. that won't happen overnight. it could take several years. how about alexon. and it's currently doing a billion dollars, we like it so much on this show, you know that. it's growing like gang busters. if vertex could be $6 billion in sales, doing comps here, the company worths to be worth at least as that of ale x ion. the data may turn out to be less positive. everything leads me to think that the drug will get approved. i am trying to put numbers on things. vertex, a catalyst on things. on thursday, it will present its final two data on the north american cystic fibrosis. once we get final results, that will allow the company to put the worries about the misinterpretation of the interim data behind it, and based on what we've seen so far, the data next week will be pretty darn good. i want to get ahead of the conference, but only if you can stomach the risk. bottomline? the lesson from serepta? it pays to invest in biotechs who are developing orphan drugs? just

i was doing the research on gilead. >> buy, buy, buy! >> it may be the strongest in the group.ogen had a good quarter. let's go to janet in new york. janet? >> caller: boo-yeah, jim. i love you and i love your show. >> i'll take that any day. you're in jersey. i'm looking for a place to stay for a couple of days. what's up? >> caller: dri, what do you think? >> here's the problem with darden. the stock had a big run. it's got a good yield. then it did nothing after that. it's going down. i think you wait until 50 and then you just buy it. that's the level that people come in and want the stock. let's go to nebraska. with. >> caller: i just want to know on saas. can you double my money in the next year? >> can you you double that? i like cloud. it's a good business. it's a $5 stock. let me do more work on it, if i like it i'll do a full feature on it by the end of the week. that's my promise to you. let's go to lee in california. lee? >> caller: boo-yeah, mr. cramer. thank you for preventing me from making lots of stupid trades and losing lots of money. >> that's what i can do b

i like celgene and gilead because they have great drugs in the pipeline.na is offered it to be a takeover target. i can't recommend stocks on the basis of that. i say take off half. don in colorado. >> jim, a big larod though rocky mountain high boo-yah to you. >> let me give you a peyton manning destroyed me on fantasy boo-yah. what's up? >> me, too. my stock -- >> a specialty chemical company. i can give you dupont, which has a good yield, good management and is less expensive. james in wisconsin. >> hey jim. >> hey james. >> boo-yah. >> boo-yah. >> what is the best time to invest in wwe, before or after wrestlemania? >> how about no time? one of those things, you give me that the either/or, i've got to give you the know because i don't think this stock is worth owning. it's got no growth. a yield but no growth is not enough for me to be tim in georgia. >> a big downtown boo-yah to you. i was calling to ask you about facebook. they're going up or down? >> look, there is going to be a couple lockups that expire where there is going to be hundreds of milli

long as the growth lasts and think about apple or whole foods and amazon, biotech comes and amgen, gilead, gone like the old drug companies, when big pharma was synonymous with growth, how do you analyze growth? when we buy a stock, we're paying for a company's expected future earnings per share. that's right. i will repeat that. expected future earnings. not past, future. a lot of people calling with the past past. it's the basket valuation, the share price, equals the earnings per share, e, times what's known as the multiple. m. e times m equals p. this tells you what investors are willing to fork over. remember this blew me away when i got to goldman sachs, we're solving for m. and the most important determiner of what price earnings multiple, the vital ingredient on the size of the valuation? it's the company's growth rate. that's why we pay so much attention. the growth rate is what rattles people more than anything else. earnings will get larger in years ahead. the stock can trade up to a multiple that's as high as two times -- twice the long-term growth rate before it gets too expe

i have to admit gilead is better. >>> coming up, double standard? both tech giants revealed results that fell short of expectations. but why is amazon stock surging while apple falls flat? cramer is pulling back the curtain on today's action. >>> two great companies, two different standards. one totally rigorous and one not rigorous enough. apple versus amazon. apple reported a number extraordinary by any means, except by the means of wall street, where it was considered horribly disappointing, as if the company is a bunch of brainless, arrogant bozos who couldn't shine steve jobs' shoes. ipod, ipad, all below what the street was looking for. at one point, down 18 points, stunning. but it rebounded. first, the company has too many products. mostly with the wrong price points. not selling well. too much inventory and can't make enough and beat the estimates. doofuses. second, can't meet demand, not enough inventory, shortfalls, chowder heads. and apple ipad sold dramatically, a glut developing, and the ipad mini, which no one wants or needs doesn't h

i have to admit gilead is better. >>> coming up, double standard?tech giants revealed results that fell short of expectations. but why is amazon stock surging while apple falls flat? cramer pulling back the curtain on today's action. [ male announcer ] zeebox is the free app that makes watching tv even better. if your tv were a "ship in a bottle", zeebox would be a cage of seagulls. [ seagulls squawking ] pair a ship in a bottle with the melody of seagulls, and you have "atmosphere" and "ambience..." you my friend are downright nautical. download zeebox, free and feel like the captain of your tv. ♪ [ male announcer ] every car we build must make adrenaline pump and pulses quicken. ♪ to help you not just to stay alive but feel alive. the new c-class is no exception. it's a mercedes-benz, through and through. see your authorized mercedes-benz dealer for exceptional offers through mercedes-benz financial services. you. we know you. we know you have to rise early... and work late, with not enough sleep in between. how you sometimes need to get over to t

i have to admit gilead is better. >>> coming up, double standard?h tech giants revealed results that fell short of expectations. but why is amazon stock surging while apple falls flat? cramer pulling back the curtain on today's action. questions? anyone have occasional constipation, diarrhea, gas, bloating? yeah. one phillips' colon health probiotic cap each day helps defend against these digestive issues with three strains of good bacteria. approved! [ phillips' lady ] live the regular life. phillips'. prove it. enough is enough. d-con no view, no touch trap snaps to kill instantly. no looking, no touching. d-con. get out. new pink lemonade 5-hour energy? 5-hour energy supports the avon foundation for women breast cancer crusade. so i can get the energized feeling i need and support a great cause? i'm sold. pink lemonade 5-hour energy? yeah and a portion of every sale goes to the avon foundation for women breast cancer crusade. i'm sold. new pink lemonade 5-hour energy. get the alert, energized feeling you need and support breast cancer research an

i have to admit gilead is better. >>> coming up, double standard?oth tech giants revealed results that fell short of expectations. but why is amazon stock surging while apple falls flat? cramer pulling back the curtain on today's action. [ male announcer ] how do you trade? with scottrader streaming quotes, any way you want. fully customize it for your trading process -- from thought to trade, on every screen. and all in real time. which makes it just like having your own trading floor, right at your fingertips. [ rodger ] at scottrade, seven dollar trades are just the start. try our easy-to-use scottrader streaming quotes. it's another reason more investors are saying... [ all ] i'm with scottrade. on gasoline. i am probably going to the gas station about once a month. last time i was at a gas station was about...i would say... two months ago. i very rarely put gas in my chevy volt. i go to the gas station such a small amount that i forget how to put gas in my car. [ male announcer ] and it's not just these owners giving the volt high praise. volt

long as the growth lasts and think about apple or whole foods and amazon, biotech comes and am zen, gileade old drug companies, when big pharma was synonymous with growth, how do you analyze growth? when we buy a stock, we're paying for a company's expected future earnings per share. that's right. i will repeat that. expected future earnings. not past, future. a lot of people calling with the past past. it's the basket valuation, the share price, equals the earnings per share, e, times what's known as the multiple. m. e times m equals p. this tells you what investors are willing to fork over. remember this blew me away when i got to goldman sachs, we're solving for m. and the most important determiner of what price earnings multiple, the vital ingredient on the size of the valuation? it's the company's growth rate. that's why we pay so much attention. the growth rate is what rattles people more than anything else. earnings will get larger in years ahead. the stock can trade up to a multiple that's as high as two times -- twice the long-term growth rate before it gets too expensive for the

gilead, pretty decent. not a whole lot of movement there. finally, vm wear reported as well.ecent numbers, up 1%. back to you, maria. >> all right, brian. thank you so much. big movers in the extended hours. what do the earnings tea leaves tell us about the direction of the broader market? ron and herb read those tea leaves for us. we have about 25% of companies reporting earnings so far. 60% are beating expectations, guys. i mean, 25%, a quarter of all of the earnings are out. does this really tell us the full picture of what's going on out there, or are we jumping the gun here by thinking that everything has sort of, you know, fallen apart with earnings, herb? >> oh, i think we now know from what we're seeing companies reporting that things are more tepid than people expected. you just see it. by the way, i don't pay attention as much to the issue of whether they're meeting or beating on this because those are numbers that can be, you know, made up or whatever. but i really think right now when you look at the earnings, and i've been going through company after company afte

. >> among your top five holdingses you have gilead in there, so that goes toward the technology and development of drugs. how about some of the other best picks in your portfolio right now? >> well, one that i want to share with the audience is a little small cap called pcrx and i'm really excited about this one. it's very early days. a single product company. so realize that there is risk here. it will be volatile. but they have an fda approved product for a long acting injectable anesthetic, all very fancy words to basically say when a patient has an operation, this is something that the physician can inject that gives long extended pain relief. and i actually think this is a very elegant -- >> do you know what kind of market cap? >> sub a billion. we're in the very early days of launch. but it's this type of product that actually brings a very substantial benefit to a patient. reduction in pain medicines, possibly earlier discharge from hospital. hasn't been demonstrated in a definitive manner, but if those things play out, this is going to be an important product in the surgical

. >> gilead upgraded. >> it goes higher.ll not expensive. >> sterne takes finish line from a sell to a hold. >> i like that call. >> credit suisse initiates abercrombie with a -- >> sell. teen ainge apparel, if you can figure them out, god love you. >> lowe's recommended by morgan stanley. >> i think the stock should be moving higher on this. the home group is still strong. >> what's tonight? >> i like to do real estate investment trusts. they have a better handle on what's going on in the economy. >> see you tonight. 6:00 and 11:00 eastern time. ism is after the break. don't go away. don't be modest, bob. you found a better way to pack a bowling ball. that was ups. and who called ups? you did, bob. i just asked a question. it takes a long time to pack a bowling ball. the last guy pitched more ball packers. but you... you consulted ups. you found a better way. that's logistics. that's margin. find out what else ups knows. i'll do that. you're on a roll. that's funny. i wasn't being funny, bob. i know. i have a cold, and i to

another standout stock, gilead sciences is up 70% year-to-date, ubs has it as its top large tech biotechng to a discount to the biotech sector, biogen up 50% in the past year thanks to its strong earnings performance and anticipation riding behind its multiple sclerosis drug bg12 which could get approval by year's end. another is buyout speculation. the firms are on the hunt for under the radar biotech firms, bristol-myers among others making big bets. andrew you've been following that as well. >> thank you for that report. lot of beta. see if there's any alpha. >>> in the next hour of "squawk box" former ubs american chairman robert wolf will join us to talk financials, jobs and the election, mr. obama's favorite banker. and later health care, a major issue for americans in the presidential candidates, the coo of mt. sinai, ken david, is going to join us. a crash management system and the world's only tridion safety cell which can withstand over three and a half tons. small in size. big on safety. which can withstand over three and a half tons. if we want to improve our schools... ...wh

we'll begin with gilead. >> this is an up stock. >> upgraded over at lazard today.oot locker, ubs says buy it. >> foot locker, remember nike was great in north america. so foot locker should be a good reason. i agree with ubs. >> goldman says a short squeeze possible at safeway. >> the days when you recommend a stock on a short squeeze, that's old days. i don't like it. >> abkrob and fitch -- >> don't bother. >> texas instrumented downgraded -- >> this thing is so cheap and no one cares. >> and medical properties trust? >> you asked me where are people going. they're going to 7% yielders if the balance sheet is going and smgt good. this is 7%. that's the solution, carl. >> i think the eyeroll quotient on that "six in 60" was the highest ever. more tonight about -- >> healthy week. we have some good names this week. and i'm unveiling a group of stocks that cannot -- that can't be stopped because there's money managers who want to show they own them, two a day for the rest of the week. the anointed ones. >> i like that. a blessed stock and the anointed stock. we've no

. >> ubs boosting on gilead? >> i think it will go much higher. >> and priceline?ine had lost its luster. it's coming right back. they never seem to die. >> want to draw your attention to kfrt to 58 or 54, something like that. it could be an erroneous trade. >> it didn't adjust properly yesterday. this is a catchup. this is going to be a big secret and kept from you. it doesn't work like that in this market. >> here's a look an intraday? >> i think the stock goes higher and it's the right push. i think these things happen, carl, and nobody cares. it just kind of happens. too bad. i blame him and he blames them. there's never a straight story because high frequency trading controls. >> they are in charge. >> what's tonight? >> vf corp, a company that just came back from china, one of the great ceos in this country, looking forward to seeing him. >> when we come back, after a short break, we'll talk about the presidential debate tonight and a lot more as we continue to watch ipos here at the big board. back in a minute. . >> announcer: today on the close bell, joe to

the bell of the biotech ball is gilead. >> we'll talk dollar tree after the bell.s a ceo triple header on "squawk." live interviews with lloyd blankfein, ron shaich on earnings and in the world of tech, scott mcgregor will join us in the next half hour. opening bell comes after this break. [ male announcer ] this is joe woods' first day of work. and his new boss told him two things -- cook what you love, and save your money. joe doesn't know it yet, but he'll work his way up from busser to waiter to chef before opening a restaurant specializing in fish and game from the great northwest. he'll start investing early, he'll find some good people to help guide him, and he'll set money aside from his first day of work to his last, which isn't rocket science. it's just common sense. from td ameritrade. >> what a week we have going. dow down 243 yesterday. last time we had two 200-plus point losses within three days. november 21 of last year. we'll see where we go today. breath is more positive at the big board. release of business insider's list of innovators in the tech